vs
Archrock, Inc.（AROC）とOrthofix Medical Inc.（OFIX）の財務データ比較。上の社名をクリックして会社を切り替えられます
Archrock, Inc.の直近四半期売上が大きい（$377.1M vs $219.9M、Orthofix Medical Inc.の約1.7倍）。Archrock, Inc.の純利益率が高く（31.0% vs -1.0%、差は32.0%）。Archrock, Inc.の前年同期比売上増加率が高い（15.5% vs 2.0%）。Archrock, Inc.の直近四半期フリーキャッシュフローが多い（$126.7M vs $16.8M）。過去8四半期でArchrock, Inc.の売上複合成長率が高い（18.5% vs 8.0%）
Archrock, Inc. は主に北米の石油・ガス分野向けに天然ガス圧縮サービスと機器ソリューションを提供する大手企業で、コア事業には圧縮システムのレンタル、保守、アフターサポート、販売が含まれ、上流生産、中流輸送、天然ガス加工分野に対応しています。
オーソフィックスメディカル社は世界的な整形外科医療機器メーカーで、脊椎インプラント、整形外科用外傷治療製品、骨成長刺激療法機器、再生医療製品の開発・製造・販売を事業としています。北米、欧州、アジア太平洋を中心に整形外科医や医療機関向けに製品を提供し、筋骨格系疾患患者の治療成績向上に取り組んでいます。
AROC vs OFIX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $377.1M | $219.9M |
| 純利益 | $116.8M | $-2.2M |
| 粗利率 | 53.0% | 71.1% |
| 営業利益率 | 39.4% | 0.2% |
| 純利益率 | 31.0% | -1.0% |
| 売上前年比 | 15.5% | 2.0% |
| 純利益前年比 | 95.4% | 92.4% |
| EPS（希薄化後） | $0.67 | $-0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $377.1M | $219.9M | ||
| Q3 25 | $382.4M | $205.6M | ||
| Q2 25 | $383.2M | $203.1M | ||
| Q1 25 | $347.2M | $193.6M | ||
| Q4 24 | $326.4M | $215.7M | ||
| Q3 24 | $292.2M | $196.6M | ||
| Q2 24 | $270.5M | $198.6M | ||
| Q1 24 | $268.5M | $188.6M |
| Q4 25 | $116.8M | $-2.2M | ||
| Q3 25 | $71.2M | $-22.8M | ||
| Q2 25 | $63.4M | $-14.1M | ||
| Q1 25 | $70.8M | $-53.1M | ||
| Q4 24 | $59.8M | $-29.1M | ||
| Q3 24 | $37.5M | $-27.4M | ||
| Q2 24 | $34.4M | $-33.4M | ||
| Q1 24 | $40.5M | $-36.0M |
| Q4 25 | 53.0% | 71.1% | ||
| Q3 25 | 48.5% | 72.2% | ||
| Q2 25 | 45.4% | 68.7% | ||
| Q1 25 | 47.4% | 62.8% | ||
| Q4 24 | 46.3% | 69.0% | ||
| Q3 24 | 44.4% | 68.7% | ||
| Q2 24 | 41.5% | 67.8% | ||
| Q1 24 | 42.1% | 67.5% |
| Q4 25 | 39.4% | 0.2% | ||
| Q3 25 | 25.3% | -8.3% | ||
| Q2 25 | 22.5% | -7.9% | ||
| Q1 25 | 26.5% | -25.2% | ||
| Q4 24 | 24.0% | -5.3% | ||
| Q3 24 | 18.1% | -9.6% | ||
| Q2 24 | 17.6% | -12.5% | ||
| Q1 24 | 20.0% | -15.6% |
| Q4 25 | 31.0% | -1.0% | ||
| Q3 25 | 18.6% | -11.1% | ||
| Q2 25 | 16.6% | -6.9% | ||
| Q1 25 | 20.4% | -27.4% | ||
| Q4 24 | 18.3% | -13.5% | ||
| Q3 24 | 12.8% | -13.9% | ||
| Q2 24 | 12.7% | -16.8% | ||
| Q1 24 | 15.1% | -19.1% |
| Q4 25 | $0.67 | $-0.05 | ||
| Q3 25 | $0.40 | $-0.57 | ||
| Q2 25 | $0.36 | $-0.36 | ||
| Q1 25 | $0.40 | $-1.35 | ||
| Q4 24 | $0.35 | $-0.76 | ||
| Q3 24 | $0.22 | $-0.71 | ||
| Q2 24 | $0.22 | $-0.88 | ||
| Q1 24 | $0.26 | $-0.95 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $1.6M | $82.0M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $1.5B | $450.0M |
| 総資産 | $4.3B | $850.6M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $1.6M | $82.0M | ||
| Q3 25 | $4.1M | $62.9M | ||
| Q2 25 | $5.9M | $65.6M | ||
| Q1 25 | $4.8M | $58.0M | ||
| Q4 24 | $4.4M | $83.2M | ||
| Q3 24 | $3.7M | $30.1M | ||
| Q2 24 | $919.0K | $26.4M | ||
| Q1 24 | $1.2M | $27.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
| Q4 25 | $1.5B | $450.0M | ||
| Q3 25 | $1.4B | $442.5M | ||
| Q2 25 | $1.4B | $458.3M | ||
| Q1 25 | $1.3B | $458.3M | ||
| Q4 24 | $1.3B | $503.1M | ||
| Q3 24 | $1.3B | $525.9M | ||
| Q2 24 | $894.5M | $546.0M | ||
| Q1 24 | $882.1M | $570.3M |
| Q4 25 | $4.3B | $850.6M | ||
| Q3 25 | $4.4B | $832.6M | ||
| Q2 25 | $4.4B | $837.2M | ||
| Q1 25 | $4.0B | $823.1M | ||
| Q4 24 | $3.8B | $893.3M | ||
| Q3 24 | $3.8B | $867.9M | ||
| Q2 24 | $2.7B | $882.0M | ||
| Q1 24 | $2.7B | $906.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $214.5M | $27.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $126.7M | $16.8M |
| FCFマージンFCF / 売上 | 33.6% | 7.6% |
| 設備投資強度設備投資 / 売上 | 23.3% | 4.9% |
| キャッシュ転換率営業CF / 純利益 | 1.84× | — |
| 直近12ヶ月FCF直近4四半期 | $119.6M | $-1.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $214.5M | $27.7M | ||
| Q3 25 | $164.5M | $12.4M | ||
| Q2 25 | $127.5M | $11.6M | ||
| Q1 25 | $115.6M | $-18.4M | ||
| Q4 24 | $124.3M | $23.7M | ||
| Q3 24 | $96.9M | $11.7M | ||
| Q2 24 | $70.7M | $9.0M | ||
| Q1 24 | $137.7M | $-18.6M |
| Q4 25 | $126.7M | $16.8M | ||
| Q3 25 | $29.5M | $2.5M | ||
| Q2 25 | $16.0M | $4.5M | ||
| Q1 25 | $-52.5M | $-25.1M | ||
| Q4 24 | $26.4M | $15.2M | ||
| Q3 24 | $26.9M | $6.3M | ||
| Q2 24 | $-20.6M | $-360.0K | ||
| Q1 24 | $37.9M | $-29.1M |
| Q4 25 | 33.6% | 7.6% | ||
| Q3 25 | 7.7% | 1.2% | ||
| Q2 25 | 4.2% | 2.2% | ||
| Q1 25 | -15.1% | -13.0% | ||
| Q4 24 | 8.1% | 7.0% | ||
| Q3 24 | 9.2% | 3.2% | ||
| Q2 24 | -7.6% | -0.2% | ||
| Q1 24 | 14.1% | -15.4% |
| Q4 25 | 23.3% | 4.9% | ||
| Q3 25 | 35.3% | 4.8% | ||
| Q2 25 | 29.1% | 3.5% | ||
| Q1 25 | 48.4% | 3.5% | ||
| Q4 24 | 30.0% | 4.0% | ||
| Q3 24 | 24.0% | 2.7% | ||
| Q2 24 | 33.7% | 4.7% | ||
| Q1 24 | 37.2% | 5.6% |
| Q4 25 | 1.84× | — | ||
| Q3 25 | 2.31× | — | ||
| Q2 25 | 2.01× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 2.08× | — | ||
| Q3 24 | 2.58× | — | ||
| Q2 24 | 2.05× | — | ||
| Q1 24 | 3.40× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AROC
| Horsepower Group Three | $112.6M | 30% |
| Horsepower Group Two | $108.5M | 29% |
| Horsepower Group One | $105.9M | 28% |
| Services | $32.9M | 9% |
| Over Counter Parts And Component Sales | $17.0M | 5% |
| Transferred At Point In Time | $1.4M | 0% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
